Takeda Pharmaceutical
317 hedge funds and large institutions have $2.45B invested in Takeda Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 101 increasing their positions, 98 reducing their positions, and 61 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 98
0.14% less ownership
Funds ownership: 9.2% → 9.06% (-0.14%)
4% less call options, than puts
Call options by funds: $78.2M | Put options by funds: $81.2M
4% less capital invested
Capital invested by funds: $2.57B → $2.45B (-$114M)
9% less funds holding
Funds holding: 347 → 317 (-30)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
46% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 61
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$26.6M |
| 2 |
GC
GMT Capital
Atlanta,
Georgia
|
+$20.4M |
| 3 |
AC
Adelphi Capital
London,
United Kingdom
|
+$18.3M |
| 4 |
GCM
Glenview Capital Management
New York
|
+$17.5M |
| 5 |
Renaissance Technologies
New York
|
+$16.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.4M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$35.1M |
| 3 |
NMC
Nine Masts Capital
Central,
Hong Kong
|
-$26.1M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$15.9M |
| 5 |
Morgan Stanley
New York
|
-$15.3M |
TAK Hedge Fund Activity: Q3 2019 in Review
317 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Takeda Pharmaceutical (TAK) for Q3 2019, worth a combined $2.45B — down 4.4% from $2.57B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of TAK and 33 opened new positions — a net loss of 28 holders — while 98 trimmed existing stakes and 101 added.
The largest buyer was Goldman Sachs, adding an estimated $26.6M. The largest seller was Fidelity Investments, cutting an estimated $36.4M.
- 317 institutional investors held Takeda Pharmaceutical (TAK) as of Q3 2019, down from 347 in Q2 2019.
- Funds reported $2.45B of Takeda Pharmaceutical stock for Q3 2019, down 4.4% quarter-over-quarter.
- 33 funds opened new Takeda Pharmaceutical positions in Q3 2019 and 61 closed out, a net change of -28 holders.
- The largest Takeda Pharmaceutical buyer in Q3 2019 was Goldman Sachs, an estimated $26.6M added.
- The largest Takeda Pharmaceutical seller in Q3 2019 was Fidelity Investments, an estimated $36.4M sold.
Based on aggregated 13F filings for Q3 2019.